Eli Lilly and Co is primarily active in the pharmaceutical industry.

The main competitors of Eli Lilly and Co in the market are pharmaceutical companies such as Pfizer, Johnson & Johnson, Merck & Co., Novartis, and Sanofi.

Eli Lilly and Co, founded in 1876, is a leading global pharmaceutical company headquartered in Indianapolis. With a rich history spanning over 140 years, Eli Lilly and Co has consistently focused on discovering, developing, and marketing innovative pharmaceutical products that improve people's lives. The company is committed to addressing crucial medical needs through its diverse portfolio of medicines and has made notable contributions in areas like diabetes, cancer, neuroscience, and immunology. Over the years, Eli Lilly and Co has established a strong reputation for its scientific expertise, ethical business practices, and dedication to ensuring patient safety and well-being.

Eli Lilly and Co, a renowned pharmaceutical company, has achieved significant milestones over the years. It pioneered the first commercially available insulin, revolutionizing diabetes treatment. The company also developed Prozac, a widely used antidepressant, contributing to mental health care. Eli Lilly collaboratively discovered Erbitux, an anti-cancer drug, which has transformed the treatment of colorectal cancer. Furthermore, the company introduced Humalog, a fast-acting insulin analog, enhancing diabetes management. Eli Lilly and Co has consistently demonstrated its commitment to innovation and improving patients' lives with its groundbreaking pharmaceutical developments.

Eli Lilly and Co is primarily present in various countries and regions worldwide. The company's global presence extends to markets such as the United States, Europe, Asia, and Latin America. With a strong foothold in the pharmaceutical industry, Eli Lilly and Co operates across multiple continents, including North America, where it is headquartered in Indianapolis, Indiana. Additionally, the company's international operations expand into key pharmaceutical markets like Canada, Germany, the UK, Japan, China, and Brazil. Ensuring a widespread reach, Eli Lilly and Co's presence remains significant on a global scale, contributing to its reputation as a leading pharmaceutical player.

Eli Lilly and Co is a renowned pharmaceutical company with a strong set of values and corporate philosophy. They prioritize patient well-being and improving lives through their innovative healthcare solutions. Their commitment to integrity and high ethical standards reflects in their extensive research and development efforts. Eli Lilly and Co aims to provide quality products that address unmet medical needs while fostering a culture of inclusivity and diversity within their organization. By consistently adhering to their core values, the company has become a global leader and a trustworthy partner in the pharmaceutical industry.

Analysts currently set an average price target of 1,164.09 USD for the Eli Lilly and Co stock (median: 1,186.26 USD), implying -2.3 % versus the latest price. The consensus is based on 37 analyst ratings.

Eli Lilly and Co Analyst Price Targets 2026

37 analysts currently rate the Eli Lilly and Co stock: 27 recommend buying, 10 holding and 0 selling. For 2026, analysts expect Eli Lilly and Co to generate revenue of 85.28 B USD and earnings per share of 35.17 USD.

Eli Lilly and Co Analyst Price Targets 2026

Converted at the current exchange rate, the Eli Lilly and Co share trades at 1,025.79 EUR (1,184.97 USD).

The Eli Lilly and Co share (LLY) is listed on 10 stock exchanges, including: NYSE (LLY), XETRA (LLY.DE), Frankfurt (LLY.F), München (LLY.MU), Düsseldorf (LLY.DU), Hamburg (LLY.HM), London (0Q1G.L), SIX (Zürich) (LLY.SW).

Eli Lilly and Co is a globally active company in the healthcare sector. Its business model focuses on developing, manufacturing, and marketing innovative drugs and healthcare products to have positive impacts on people's lives. The company operates in three main business areas: human pharmaceuticals, animal health, and biotechnology. In the field of human pharmaceuticals, the company offers a wide range of drugs for the treatment of diseases such as diabetes, cancer, arthritis, neurology, and more. Some of its well-known products include Humalog, Trulicity, Taltz, Jardiance, Forteo, and Alimta. Eli Lilly and Co is also a major player in the animal health sector, providing veterinarians and pet owners with a wide range of drugs and services. This includes specialized products for the treatment of dogs, cats, horses, cattle, pigs, and poultry. Through its biotechnology business areas, Eli Lilly and Co is also dedicated to the development of innovative therapies and technologies. It focuses on autoimmune diseases, pain management, cancer research, and affordable healthcare in emerging markets. To ensure the success of its business model, Eli Lilly and Co invests billions annually in research and development of new drugs and healthcare solutions. A significant portion of these funds goes into clinical trials to ensure the safety and efficacy of the drugs. Eli Lilly and Co intends to further expand its business by focusing on partnerships, mergers, and acquisitions to expand its portfolio and capabilities. In this context, the company has recently undertaken a number of acquisitions and partnerships, including Loxo Oncology, ImClone Systems, Sitryx, Armo BioSciences, and AC Immune. Eli Lilly and Co generates revenue worldwide by selling its products directly to retailers, collaborating closely with doctors and other medical professionals, and selling its products to wholesalers and pharmacies. The company also operates its own facilities to provide medical services and products to people and pets. In summary, Eli Lilly and Co is a leading company in the healthcare sector that aims to provide innovative and life-changing solutions for patients and pets worldwide. Through research, development, and strategic partnerships, the company has built a wide range of products and extensive expertise to effectively serve its customers and expand its presence in the global healthcare market.

The expected revenue of Eli Lilly and Co is 85.28 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Eli Lilly and Co is 31.58 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Eli Lilly and Co is currently 33.69. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Eli Lilly and Co stock.

The price-to-sales ratio (P/S) of Eli Lilly and Co is currently 12.48. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Eli Lilly and Co stock.

The Eulerpool Quality Score for Eli Lilly and Co is 7/10.

The ISIN of Eli Lilly and Co is US5324571083. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Eli Lilly and Co is 858560. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Eli Lilly and Co is LLY. The ticker symbol is used to trade Eli Lilly and Co shares on the stock exchange.

Over the past 12 months, Eli Lilly and Co paid a dividend of 6.00 USD . This corresponds to a dividend yield of about 0.51 %. For the coming 12 months, Eli Lilly and Co is expected to pay a dividend of 7.97 USD.

The current dividend yield of Eli Lilly and Co is 0.51 %.

Eli Lilly and Co pays a dividend, distributed in the months of , , , .

Eli Lilly and Co paid dividends every year for the past 36 years.

For the upcoming 12 months, dividends amounting to 7.97 USD are expected. This corresponds to a dividend yield of 0.69 %.

Eli Lilly and Co is assigned to the 'Health' sector.

In the year 2025, Eli Lilly and Co distributed 5.4 USD as dividends.

The dividends of Eli Lilly and Co are distributed in USD.